Literature DB >> 9336020

Pharmacology of cannabinoid CB1 and CB2 receptors.

R G Pertwee1.   

Abstract

There are at least two types of cannabinoid receptors, CB1 and CB2, both coupled to G-proteins. CB1 receptors are present in the central nervous system and CB1 and CB2 receptors in certain peripheral tissues. The existence of endogenous cannabinoid receptor agonists has also been demonstrated. These discoveries have led to the development of selective cannabinoid CB1 and CB2 receptor ligands. This review focuses on the classification, binding properties, effector systems and distribution of cannabinoid receptors. It also describes the various cannabinoid receptor agonists and antagonists now available and considers the main in vivo and in vitro bioassay methods that are generally used.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9336020     DOI: 10.1016/s0163-7258(97)82001-3

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   12.310


  345 in total

1.  Pharmacological analysis of cannabinoid receptor activity in the rat vas deferens.

Authors:  A Christopoulos; P Coles; L Lay; M J Lew; J A Angus
Journal:  Br J Pharmacol       Date:  2001-03       Impact factor: 8.739

2.  Agonist-induced internalization and trafficking of cannabinoid CB1 receptors in hippocampal neurons.

Authors:  A A Coutts; S Anavi-Goffer; R A Ross; D J MacEwan; K Mackie; R G Pertwee; A J Irving
Journal:  J Neurosci       Date:  2001-04-01       Impact factor: 6.167

3.  Presynaptically located CB1 cannabinoid receptors regulate GABA release from axon terminals of specific hippocampal interneurons.

Authors:  I Katona; B Sperlágh; A Sík; A Käfalvi; E S Vizi; K Mackie; T F Freund
Journal:  J Neurosci       Date:  1999-06-01       Impact factor: 6.167

4.  Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656, and AM630.

Authors:  R A Ross; H C Brockie; L A Stevenson; V L Murphy; F Templeton; A Makriyannis; R G Pertwee
Journal:  Br J Pharmacol       Date:  1999-02       Impact factor: 8.739

5.  Novel 1',1'-chain substituted hexahydrocannabinols: 9β-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol (AM2389) a highly potent cannabinoid receptor 1 (CB1) agonist.

Authors:  Spyros P Nikas; Shakiru O Alapafuja; Ioannis Papanastasiou; Carol A Paronis; Vidyanand G Shukla; Demetris P Papahatjis; Anna L Bowman; Aneetha Halikhedkar; Xiuwen Han; Alexandros Makriyannis
Journal:  J Med Chem       Date:  2010-10-14       Impact factor: 7.446

Review 6.  Cannabinoids and the gastrointestinal tract.

Authors:  R G Pertwee
Journal:  Gut       Date:  2001-06       Impact factor: 23.059

7.  Assessment of Biased Agonism among Distinct Synthetic Cannabinoid Receptor Agonist Scaffolds.

Authors:  Elise Wouters; Jolien Walraed; Michael Joseph Robertson; Max Meyrath; Martyna Szpakowska; Andy Chevigné; Georgios Skiniotis; Christophe Stove
Journal:  ACS Pharmacol Transl Sci       Date:  2019-11-04

8.  Controlled-deactivation cannabinergic ligands.

Authors:  Rishi Sharma; Spyros P Nikas; Carol A Paronis; Jodianne T Wood; Aneetha Halikhedkar; Jason Jianxin Guo; Ganesh A Thakur; Shashank Kulkarni; Othman Benchama; Jimit Girish Raghav; Roger S Gifford; Torbjörn U C Järbe; Jack Bergman; Alexandros Makriyannis
Journal:  J Med Chem       Date:  2013-12-10       Impact factor: 7.446

Review 9.  Cannabinoid Receptors in Diabetic Kidney Disease.

Authors:  F Barutta; R Mastrocola; S Bellini; G Bruno; Gabriella Gruden
Journal:  Curr Diab Rep       Date:  2018-02-05       Impact factor: 4.810

Review 10.  Pharmacokinetics and pharmacodynamics of cannabinoids.

Authors:  Franjo Grotenhermen
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.